Gilead shifting access to potential coronavirus drug to clinical trials
NEW YORK, March 22 (Reuters) - Gilead Sciences Inc said on Sunday it was temporarily putting emergency access to its experimental coronavirus drug remdesivir on hold due to overwhelming demand and that it wanted most people receiving the drug to participate in a clinical trial to prove if it is safe and effective. The drugmaker said in a statement there had been an exponential increase in so-called compassionate-use requests for the drug. It was shifting from a system of individual compassionate-use requests to expanded access programs, ...
Click
To Read Full Article